At Aiolos Bio, we are dedicated to revolutionizing the treatment landscape for respiratory disease and other immunological disorders. Our goal is to provide patients and caregivers with more efficacious therapies that significantly reduce treatment burden. Our vision is embodied in our current focus – the development of a groundbreaking anti-TSLP therapy with best-in-class potential. We are a San Francisco Bay area-based clinical stage biopharma company with additional operations in London, UK. The Aiolos team is comprised of seasoned drug developers, who have successfully developed and launched products for a range of immune conditions, including asthma, rheumatoid arthritis, IPF, and more. As we grow, we will look to add like-minded individuals to our team - those committed to the goal of providing a meaningful difference in the lives of patients suffering from respiratory illnesses and other immune disorders.
Location: United States, California, San Francisco
Employees: 11-50
Total raised: $245M
Founded date: 2023
Investors 3
| Date | Name | Website |
| - | Forbion | forbion.co... |
| 25.10.2023 | Sofinnova ... | sofinnova.... |
| 26.10.2023 | Atlas Vent... | atlasventu... |
Funding Rounds 1
| Date | Series | Amount | Investors |
| 25.10.2023 | Series A | $245M | - |
Mentions in press and media 8
| Date | Title | Description |
| 02.05.2024 | Forbion Portfolio Company Mariana Oncology to be Acquired by Novartis to Advance Precision Radiopharmaceuticals to Treat Cancer | • Latest deal marks the fifth Forbion portfolio company to be acquired for over $1 bn within a year Naarden, The Netherlands, 2 May 2024 - Forbion portfolio company Mariana Oncology (Mariana) is to be acquired by Novartis for $1 billion in ... |
| 22.04.2024 | Forbion co-leads $75m Series B Financing in SynOx Therapeutics | •Financing co-led by Forbion, HealthCap and new investor Bioqube Ventures •Funds will be used for pivotal trial of potential best-in-class, next-generation treatment for Tenosynovial Giant Cell Tumour Dublin, Ireland and Oxford, UK, 22 Apri... |
| 18.01.2024 | VectorY appoints Khurem Farooq to Board of Directors | · CEO and Co-Founder of Aiolos Bio and previous CEO of Gyroscope Khurem Farooq joins as independent board member |
| 12.01.2024 | JPM brings pharma firepower, but services quiet | The JPMorgan Health Care Conference ended with more than $10 billion in deal announcements, setting a bullish tone for pharma and biotech M&A in 2024. Yes, but: There was a notable lack of large-scale deal announcements in any health se... |
| 25.10.2023 | Aiolos Bio Raises $245M in Series A funding | Aiolos Bio, a San Francisco, CA-based clinical-stage biopharmaceutical company, raised $245M in Series A funding. The round was led by Atlas Venture, Bain Capital Life Sciences, Forbion, and Sofinnova Investments with additional investment ... |
| 24.10.2023 | Aiolos Bio Launches With $245M As Asthma-Focused Funding Accelerates | 8 Shares Email Facebook Twitter LinkedIn Venture investors have long been keen backers of startups working on treatments for asthma and other respiratory ailments. Lately, it looks like activity is scaling up further. On Tuesday, San Franci... |
| 24.10.2023 | Forbion co-leads $245 million Series A financing of Aiolos | • Series A financing round co-led by Forbion, Atlas Venture, Bain Capital Life Sciences, and Sofinnova Investments with additional investment from RA Capital Management. • Aiolos Bio is focused on addressing the unmet needs of patients with... |
| 24.10.2023 | Aiolos Bio Launches with $245 Million Series A Investment to Advance Development of Novel, Phase 2-Ready TSLP Antibody | - |